Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai Fosun Pharmaceutical (Group) Co (OTCPK:SFOSF) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Shanghai Fosun Pharmaceutical (Group) Co's Enterprise Value for the quarter that ended in Mar. 2026 was $12,834 Mil.
Shanghai Fosun Pharmaceutical (Group) Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $900 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Fosun Pharmaceutical (Group) Co EV-to-EBIT Related Terms
Shanghai Fosun Pharmaceutical (Group) Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Fosun Pharmaceutical (Group) Co EV-to-EBIT Chart
Shanghai Fosun Pharmaceutical (Group) Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fosun Pharmaceutical (Group) Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Fosun Pharmaceutical (Group) Co EV-to-EBIT vs Drug Manufacturers Industry
Shanghai Fosun Pharmaceutical (Group) Co's current Enterprise Value is $14,278 Mil.
Shanghai Fosun Pharmaceutical (Group) Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $900 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) has a EV-to-EBIT of 15.86 as of Jul. 14, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Shanghai Fosun Pharmaceutical (Group) Co and its competitors. This is 17% below median its historical median of 19.19. Over the past decade, Shanghai Fosun Pharmaceutical (Group) Co's EV-to-EBIT has ranged from 11.05 to 35.99. According to the industry distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #332 out of 688 companies in the Drug Manufacturers industry, placing it in the top 48.3%.
Is Shanghai Fosun Pharmaceutical (Group) Co's EV-to-EBIT too high?
Shanghai Fosun Pharmaceutical (Group) Co's current EV-to-EBIT of 15.86 is 17% below median its 10-year median of 19.19. Over the past 10 years, this metric has ranged from a low of 11.05 to a high of 35.99. The Drug Manufacturers industry median EV-to-EBIT is 15.84. Shanghai Fosun Pharmaceutical (Group) Co's value of 15.86 is 0.1% above this industry median. Based on the distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #332 out of 688 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Shanghai Fosun Pharmaceutical (Group) Co has a GF Scoreâ„¢ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Fosun Pharmaceutical (Group) Co's EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #332 out of 688 companies for EV-to-EBIT. This puts Shanghai Fosun Pharmaceutical (Group) Co in the upper half of its industry. The industry median EV-to-EBIT is 15.84. Shanghai Fosun Pharmaceutical (Group) Co's value of 15.86 is 0.1% above this benchmark. Historically, Shanghai Fosun Pharmaceutical (Group) Co's own EV-to-EBIT has ranged from 11.05 to 35.99 over the past decade. While the company's 10-year median is 19.19 vs. the industry median of 15.84, Shanghai Fosun Pharmaceutical (Group) Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.84, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Fosun Pharmaceutical (Group) Co's current EV-to-EBIT of 15.86 is 0.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Shanghai Fosun Pharmaceutical (Group) Co and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Fosun Pharmaceutical (Group) Co's current EV-to-EBIT is 15.86, which is 17% below median its own 10-year median of 19.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Fosun Pharmaceutical (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.47, compared to a current price of $2.20 — trading 10.9% below its estimated fair value. The current EV-to-EBIT is 15.86, which is 17% below median its 10-year median of 19.19 and 0.1% above the Drug Manufacturers industry median of 15.84. Shanghai Fosun Pharmaceutical (Group) Co's overall GF Score™ is 77/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Shanghai Fosun Pharmaceutical (Group) Co (SFOSF), the current EV-to-EBIT is 15.86 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co stock appears to be undervalued.
The current stock price of $2.20 is trading 10.9% below its estimated GF Value™ of $2.47.
GuruFocus considers Shanghai Fosun Pharmaceutical (Group) Co to be Modestly Undervalued.
Key valuation signals for SFOSF:
EV-to-EBIT: 15.86 (17% below median its 10-year median of 19.19)
GF Value™: $2.47 vs. price of $2.20 (10.9% below fair value)
Industry Position: 0.1% above the Drug Manufacturers median (#332 of 688)
No single metric tells the full story. See the SFOSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Fosun Pharmaceutical (Group) Co Business Description
Shanghai Fosun Pharmaceutical (Group) Co Ltd is engaged in the development, manufacture, sale of pharmaceutical products and medical equipment, the import and export of medical equipment, and the provision of related and other consulting services and investment management. Its business segments are Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. It generates the majority of its revenue from the Pharmaceutical manufacturing segment. The company considers mergers and acquisitions as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities. Its geographic areas are the Chinese mainland, Regions outside the Chinese mainland, and other countries.
77GF Score
Get the complete analysis for SFOSF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SFOSF has been successfully added to your 
